TGFB1 and cancer: It has been established that: (i) circulating myeloid-derived DCs from cancer patients reduce activation and Th1 cytokine production in an IL-10 and TGF-β-dependent manner in iNKT cells [20]; (ii) TAMs reduce both iNKT cell proliferation and cytokine production in a PD-1-dependent manner [21]; (iii) Tregs reduce immunosurveillance by decreasing iNKT cell number and cytotoxic activity [22]; and (iv) MDSCs suppress iNKT antitumor activity [23].